Health Canada approves VPRIV enzyme replacement therapy for type 1 Gaucher disease
Links shared publicly online about this topic.
- 687total visits
Health Canada approves VPRIV enzyme replacement therapy for type 1 Gaucher disease
Shire plc, the global specialty biopharmaceutical company, announces that Health Canada has approved VPRIV (velaglucerase alfa), an enzyme replacement therapy (ERT) for long-term use in pediatric and adult type 1 Gaucher disease.
View full resource at news-medical.net
Tags: Lipid Storage Disease, Gaucher Disease, Disease and Condition, Healthy Living, Children's Health, Shire, disease
Most Recently Shared on December 1, 2010 at 12:14 pm By:
Health Canada approves VPRIV enzyme replacement therapy for type 1 Gaucher disease: Shire plc, the global specia... http://bit.ly/eXIaXq
VPRIV® (velaglucerase Alfa) Approved In Canada For The Treatment Of Type I Gaucher Disease
medicalnewstoday.com — “Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that Health Canada has approved VPRIV (velaglucerase alfa), an enzyme replacement therapy (ERT) for l” View full resource at medicalnewstoday.com
Most Recently Shared on December 4, 2010 at 2:41 pm By:
VPRIV® (velaglucerase Alfa) Approved In Canada For The Treatment Of Type I Gaucher Disease… http://goo.gl/fb/BpI84
Advertisement
